Clinical Trial Update: Efficacy, Safety & Tolerability of Switching EFV/TDF/FTC to BIC/FTC/TAF in Virologically Suppressed Adults With HIV-1 [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating efficacy, safety, and tolerability when switching virologically suppressed HIV-1 adults from EFV/TDF/FTC to BIC/FTC/TAF.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Immunodeficiency Virus

Drugs mentioned

• Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate)
• BIKTARVY (BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE)

Snippet

Sponsor: Midland Research Group, Inc. | Conditions: Human Immunodeficiency Virus | Phase 4 | Status: COMPLETED